VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry.

Trial Profile

VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry.

Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Telavancin (Primary)
  • Indications Enterococcal infections; Nosocomial pneumonia; Skin and soft tissue infections; Staphylococcal infections; Streptococcal infections
  • Focus Adverse reactions
  • Sponsors Astellas Pharma; Innoviva
  • Most Recent Events

    • 24 May 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top